Last Updated: November 16, 2026

Details for Patent: 8,846,074

« Back to Dashboard


Which drugs does patent 8,846,074 protect, and when does it expire?

Patent 8,846,074 protects KYNMOBI and is included in one NDA.

This patent has thirty-nine patent family members in twenty countries.

Summary for Patent: 8,846,074
Title:Sublingual films
Abstract:The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Inventor(s):Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
Assignee: Sunovion CNS Development Canada ULC , Sumitomo Pharma America Inc
Application Number:US13/858,638
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

United States Patent 8,846,074: Apomorphine Sublingual Film Claims, Patent Scope, and Kynmobi Landscape

US Patent 8,846,074 protects a multilayer sublingual film containing apomorphine hydrochloride in one layer and high-concentration pyridoxine in another. The patent also covers specified plasticizers, starch derivatives, antioxidants, permeation enhancers, cellulose polymers, dose strengths, rapid systemic exposure, and treatment of Parkinson's disease.

The principal commercial relevance is KYNMOBI, Sunovion Pharmaceuticals' apomorphine hydrochloride sublingual film for intermittent treatment of “off” episodes in patients with Parkinson's disease. The patent is composition-focused, but its dependent claims create several formulation and performance-based infringement positions.

What does US Patent 8,846,074 protect?

The broadest independent claim protects a pharmaceutical composition with five core limitations:

  1. The product is in unit dosage form.
  2. The dosage form is a film.
  3. The film is formulated for sublingual administration.
  4. The film has a first layer containing 2 to 60 mg of apomorphine hydrochloride.
  5. The second layer contains pyridoxine at 25±5% to 65±5% by weight.

Claim 1 does not require every excipient later recited in the dependent claims. A competing product could therefore fall within claim 1 without containing a polyol, hydrolyzed starch, metabisulfite, glycerol monostearate, or a specified cellulose polymer.

Claim element Scope
Active ingredient Apomorphine hydrochloride
Active-ingredient amount 2 to 60 mg per unit dosage form
Dosage form Film
Route Sublingual administration
Film architecture First layer and second layer
First layer Contains apomorphine hydrochloride
Second layer Contains pyridoxine
Pyridoxine concentration Approximately 20% to 70% under the stated ±5% formulation tolerance
Independent treatment claim Sublingual administration for Parkinson's disease

The claim is narrower than a claim to any apomorphine oral film. It requires a two-layer construction and pyridoxine in the second layer. A single-layer film, a buccal film without sublingual administration, or a film using a different pH-neutralizing agent may avoid literal infringement of claim 1, subject to claim construction and the doctrine of equivalents.

How should the pyridoxine limitation be interpreted?

Pyridoxine is a central claim limitation, not a peripheral excipient. Claim 1 requires pyridoxine in the second layer at a stated concentration range. Claim 18 further specifies a second layer containing 65±5% pyridoxine. Claim 19 links the pyridoxine content to a pH result in unbuffered water.

The claims present three related but distinct limitations:

Claim Pyridoxine requirement
Claim 1 25±5% to 65±5% by weight in the second layer
Claim 18 65±5% by weight in the second layer
Claim 19 Amount sufficient to produce pH 2.5 to 8.0 in 1 mL of unbuffered water at pH 7

Claim 19 is functional and test-dependent. In litigation, the parties would likely dispute the testing protocol, including:

  • Whether the entire film or only the second layer is tested.
  • The water temperature and equilibration time.
  • Whether the film is fully dissolved before pH measurement.
  • The meaning of “unbuffered water at pH 7.”
  • Whether the pH measurement must be performed on a defined film mass or one complete unit dose.

A generic or follow-on developer could attempt design-around protection by using a different neutralizing agent, placing pyridoxine outside the second layer, using a different concentration, or changing the layer architecture. The commercial and litigation value of that strategy would depend on the specification, prosecution history, and any related continuation claims.

What formulations are protected by the dependent claims?

The dependent claims create a nested formulation estate around the basic apomorphine-pyridoxine film.

Plasticizer claims

Claims 2 through 4 cover 3% to 12% by weight of a plasticizing agent. The claimed materials include:

  • Sorbitol
  • Mannitol
  • Maltitol
  • Xylitol
  • Glycerol
  • Propylene glycol
  • Polyethylene glycol
  • Oleic acid
  • Triacetin

These claims address film flexibility, handling, dissolution, and manufacturing properties. A formulation containing a plasticizer outside the 3% to 12% range may avoid literal infringement of claim 2, but would remain exposed to claim 1 if the core two-layer and pyridoxine limitations are satisfied.

Hydrolyzed starch claims

Claims 5 and 6 cover 1% to 50% by weight of hydrolyzed starch, including:

  • Dextrin
  • Maltodextrin

These limitations may be important for film formation, mechanical strength, dissolution, and uniformity. A product using an unhydrolyzed starch, a synthetic polymer, or a different carbohydrate may avoid these dependent claims while remaining within claim 1.

Antioxidant and metabisulfite claims

Claims 7 and 8 cover an antioxidant and specifically 0.05% to 2.5% metabisulfite. These limitations address apomorphine stability, because apomorphine is susceptible to oxidative degradation.

The metabisulfite limitation is relatively concrete and potentially easier to test analytically than a broad antioxidant claim. A formulation using ascorbate, tocopherol, another sulfite concentration, or an oxygen-control strategy could avoid claim 8.

Permeation-enhancer claims

Claims 9 and 10 cover 0.2% to 5% of a permeation enhancer, specifically glycerol monostearate. A product using a different permeation enhancer could avoid claim 10 but remain within claim 9 if the substitute falls within the broader functional class recognized by the claim construction.

Cellulose-polymer claims

Claim 11 covers films containing one or more of the following:

  • Carboxymethylcellulose
  • Hydroxypropyl cellulose
  • Hydroxypropyl methylcellulose
  • Hydroxyethyl cellulose
  • Methyl cellulose

These polymers are common film-forming or viscosity-modifying materials. Their use may create a straightforward dependent-claim infringement theory if the accused product's composition is disclosed in regulatory or manufacturing records.

What dose strengths are covered by US 8,846,074?

Claims 13 through 16 cover four dose bands:

Claim Apomorphine hydrochloride per unit
Claim 13 12±3 mg
Claim 14 22±4 mg
Claim 15 30±5 mg
Claim 16 35±5 mg

These ranges correspond approximately to:

  • Claim 13: 9 to 15 mg
  • Claim 14: 18 to 26 mg
  • Claim 15: 25 to 35 mg
  • Claim 16: 30 to 40 mg

The ranges overlap. A 30 mg unit, for example, may fall within claims 15 and 16, depending on the product's labeled and measured content. The overlap increases the number of potentially asserted claims but may also create claim-construction and invalidity issues if the ranges are not supported by distinct technical effects.

Claim 1 permits 2 to 60 mg, making it broader than the expressly recited dose claims. A product containing 45 mg could potentially satisfy claim 1 while avoiding claims 13 through 16.

Does the patent cover rapid apomorphine absorption?

Claim 12 requires that sublingual administration produce an average circulating concentration of at least 3 ng/mL within 5 to 15 minutes.

This is a pharmacokinetic limitation. Its enforcement value depends on whether the claim is interpreted as requiring:

  • A specific clinical study design.
  • A defined patient population.
  • A defined blood or plasma matrix.
  • A specified sampling schedule.
  • A particular method for calculating the average concentration.
  • Reproducibility across subjects or only a study average.

A competitor may avoid literal infringement if its product reaches the claimed concentration outside the specified time window. The claim may still be relevant where a product has materially similar pharmacokinetics and the patent owner asserts equivalents.

Claim 12 creates a potential regulatory-to-patent interface. FDA-approved labeling, clinical pharmacology reports, and abbreviated application materials may disclose enough pharmacokinetic information to support an infringement investigation. For a generic product, the applicant's reliance on the reference product's pharmacokinetic profile could complicate a non-infringement position.

What is the treatment-method scope?

Claim 17 covers a method of treating Parkinson's disease by administering the claimed pharmaceutical composition sublingually in an amount effective to treat the patient.

The method claim requires the underlying composition to satisfy claim 1. It does not independently cover every sublingual apomorphine product. The claim is therefore most relevant against:

  • A manufacturer inducing use of a qualifying film.
  • A distributor promoting the claimed Parkinson's treatment.
  • A product label directing sublingual use for Parkinson's disease.
  • A product whose dosing instructions necessarily practice the claimed method.

The claim may support induced-infringement allegations where an approved label instructs patients to use the product for Parkinson's “off” episodes. It is less useful against an unapproved composition that lacks the required two-layer pyridoxine structure.

What is the expected patent expiration date?

The patent's nominal term is based on the earliest effective nonprovisional or international filing date, not simply the grant date. US Patent 8,846,074 was granted in 2014, but its statutory term runs approximately 20 years from the applicable filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.

Event Approximate timing
Earliest priority and family filings 2010-era
US grant September 30, 2014
Nominal statutory expiry Approximately 2031, subject to USPTO term calculation
Patent-term adjustment Must be confirmed in USPTO Patent Center
Patent-term extension Drug-specific regulatory extension must be separately confirmed

The grant date should not be used as the expiration date. The controlling record is the USPTO patent bibliographic data and patent-term calculation. The Orange Book may list later-issued patents with different expiration dates that provide more immediate commercial protection for KYNMOBI.

What is the Orange Book status of apomorphine sublingual film products?

KYNMOBI was approved by FDA in May 2020 as apomorphine hydrochloride sublingual film for acute, intermittent treatment of “off” episodes in patients with Parkinson's disease. The product was developed by Cynapsus Therapeutics and commercialized by Sunovion Pharmaceuticals after Sunovion acquired Cynapsus in 2016.

The Orange Book analysis should distinguish three categories:

  1. Patents listed for the approved drug product.
  2. Patents in the broader Cynapsus and Sunovion patent family.
  3. Patents that cover manufacturing, formulation, or use but are not listed because they do not satisfy Orange Book listing criteria.

US 8,846,074 is commercially relevant to the KYNMOBI formulation family. However, an Orange Book entry for a particular patent must be confirmed against the current FDA Orange Book listing for the drug's NDA. Patent ownership, listing status, and enforceability are separate questions.

FDA regulatory milestones

Milestone Date
Cynapsus acquisition by Sunovion 2016
FDA approval of KYNMOBI May 29, 2020
Dosage form Sublingual film
Active ingredient Apomorphine hydrochloride
Indication Acute, intermittent treatment of “off” episodes in Parkinson's disease

FDA approval does not establish patent validity or infringement. It establishes regulatory approval of the drug product and its labeled use.

Which companies are challenging the apomorphine film patents?

No publicly established commercial generic challenge can be determined solely from the claim text. A reliable Paragraph IV assessment requires current FDA Orange Book data, ANDA litigation dockets, and notices filed under 21 U.S.C. § 355(j)(2)(B).

For KYNMOBI, a Paragraph IV challenge would likely target one or more of the following:

  • Lack of novelty for a multilayer oral film.
  • Obviousness based on apomorphine films, pyridoxine-containing formulations, and buccal or sublingual delivery systems.
  • Lack of written description for the broad pyridoxine concentration range.
  • Lack of enablement across the full 2 to 60 mg apomorphine range.
  • Indefiniteness in the “25±5% to 65±5%” language.
  • Non-infringement based on a different layer arrangement or pH-modifying agent.
  • Failure to meet the pharmacokinetic limitation in claim 12.

A generic applicant could also submit a Paragraph III certification, asserting that relevant patents will expire before approval, or a section viii statement for method-of-use patents if the applicant omits the patented indication. The commercial value of those strategies depends on which patents are listed against the NDA at the time of filing.

How strong is the patent estate?

The patent has moderate-to-strong formulation coverage but limited breadth outside the specific film architecture.

Strengths

  • Claim 1 combines dosage form, route, layer structure, active ingredient, and pyridoxine.
  • The claims cover both composition and treatment method.
  • Dependent claims provide fallback positions for excipients and dose strengths.
  • Claim 12 adds a pharmacokinetic performance limitation that may distinguish slower oral or buccal products.
  • Pyridoxine in the second layer may be difficult to avoid if it is used to control local pH or improve apomorphine absorption.

Vulnerabilities

  • The core claim is crowded with structural limitations.
  • Prior-art risk is potentially significant for oral films, multilayer films, apomorphine delivery, and pyridoxine-containing formulations.
  • The unusual concentration language may create indefiniteness or construction disputes.
  • Some dependent claims recite common pharmaceutical excipients.
  • A competitor may design around the second-layer pyridoxine requirement.
  • Pharmacokinetic claims can be difficult to enforce without standardized testing and sufficient product data.

The strongest practical protection is likely the combination of the two-layer film and pyridoxine limitations, rather than any individual excipient claim.

What generic launch scenarios exist?

Scenario 1: Paragraph IV challenge

A generic applicant challenges validity or asserts non-infringement. Litigation could delay approval under the Hatch-Waxman framework, subject to the applicable 30-month stay and exclusivity provisions.

Scenario 2: Paragraph III certification

The applicant accepts the listed patent claims and schedules launch after the relevant patent expiry. This is the lowest litigation-risk pathway but delays market entry.

Scenario 3: Section viii carve-out

The applicant removes a patented method of use from its labeling. This strategy is more relevant to method claims than to composition claims. It is unlikely to avoid a composition patent if the approved generic product itself has the claimed two-layer structure and pyridoxine content.

Scenario 4: Formulation design-around

A competitor uses a single layer, a different neutralizing agent, a different pyridoxine location, or a non-film dosage form. This may reduce infringement risk but could also sacrifice the rapid absorption and patient-convenience advantages of the reference product.

What licensing and commercial factors matter?

Sunovion acquired Cynapsus for approximately $624 million in 2016, giving Sunovion control of the KYNMOBI program and associated intellectual property. The transaction indicates that the commercial value rested on the combined product, clinical program, regulatory position, and patent portfolio rather than US 8,846,074 alone.

KYNMOBI's commercial exposure is tied to the Parkinson's disease “off” episode market, where alternatives include:

  • Subcutaneous apomorphine injection.
  • Apomorphine infusion products.
  • Levodopa-based rescue therapies.
  • Other advanced Parkinson's disease therapies.

A film product can command commercial value through needle-free administration, but its market position depends on tolerability, oral-mucosal reactions, titration requirements, insurance coverage, and physician adoption.

Commercial discontinuation or limited availability would not automatically terminate the patent. Patent enforceability and product commercialization are separate issues.

How does US 8,846,074 compare with competing apomorphine products?

Product type Route Film architecture required? Pyridoxine requirement Likely exposure to US 8,846,074
KYNMOBI Sublingual Yes Yes, depending on formulation High
Apomorphine injection Subcutaneous No No Low
Apomorphine infusion Subcutaneous infusion No No Low
Generic sublingual film matching KYNMOBI Sublingual Potentially yes Potentially yes High
Single-layer oral film Oral or buccal No, if genuinely single-layer Depends on composition Lower
Non-film sublingual tablet Sublingual No Depends on composition Low
Film using another pH modifier Sublingual Potentially yes No pyridoxine or different location Fact-specific

The patent does not create a monopoly over apomorphine as an active ingredient, Parkinson's rescue treatment, or subcutaneous delivery.

Key Takeaways

  • US 8,846,074 centers on a two-layer sublingual film containing apomorphine hydrochloride and pyridoxine.
  • Claim 1 is the principal composition claim and does not require the additional excipients in the dependent claims.
  • Claims 13 through 16 cover approximately 12 mg, 22 mg, 30 mg, and 35 mg apomorphine dose bands.
  • Claim 12 adds a rapid-exposure limitation of at least 3 ng/mL within 5 to 15 minutes.
  • Claim 17 covers treatment of Parkinson's disease using the claimed composition.
  • The patent's nominal term extends approximately to 2031, subject to the official USPTO term calculation.
  • The strongest design-around routes are changing the layer structure, removing pyridoxine from the second layer, using a different neutralizing system, or abandoning the film dosage form.
  • KYNMOBI is the principal commercial product associated with this technology and was approved by FDA in 2020.
  • Generic risk depends on the current Orange Book listing, any Paragraph IV notice, later continuation patents, and the precise composition of the proposed product.
  • US 8,846,074 is a meaningful formulation patent but does not cover all apomorphine products or all Parkinson's rescue therapies.

Frequently Asked Questions

Does US 8,846,074 cover apomorphine tablets?

No. The independent claim requires a film formulated for sublingual administration. A conventional tablet would not ordinarily satisfy the film limitation.

Can a product avoid the patent by using pyridoxine in the first layer?

Potentially. Claim 1 requires pyridoxine in the second layer. The result would depend on the complete claim set, prosecution history, specification, and any doctrine-of-equivalents theory.

Does a 30 mg apomorphine film fall within multiple dose claims?

Yes, potentially. A 30 mg unit can fall within the ranges of claims 15 and 16, subject to the measured amount and the applicable tolerance interpretation.

Are apomorphine injections blocked by this patent?

Generally no. The claims require a sublingual film, while injections use a different route and dosage form.

Does FDA approval prove that the patent is valid?

No. FDA approval confirms regulatory approval of the product. Patent validity, infringement, enforceability, and Orange Book listing are separate legal questions.

References

  1. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,846,074, Sublingual film compositions.
  2. U.S. Food and Drug Administration. (2020). KYNMOBI (apomorphine hydrochloride) sublingual film prescribing information. Sunovion Pharmaceuticals Inc.
  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  4. U.S. Food and Drug Administration. (2020). FDA approves KYNMOBI for the acute intermittent treatment of “off” episodes in patients with Parkinson’s disease.
  5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
  6. Sunovion Pharmaceuticals Inc. (2016). Sunovion completes acquisition of Cynapsus Therapeutics.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,846,074

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-001 May 21, 2020 DISCN Yes No 8,846,074 ⤷  Start Trial Y TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-002 May 21, 2020 DISCN Yes No 8,846,074 ⤷  Start Trial Y TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 DISCN Yes No 8,846,074 ⤷  Start Trial Y TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 DISCN Yes No 8,846,074 ⤷  Start Trial Y TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-005 May 21, 2020 DISCN Yes No 8,846,074 ⤷  Start Trial Y TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,846,074

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011343429 ⤷  Start Trial
Australia 2017200331 ⤷  Start Trial
Australia 2019200138 ⤷  Start Trial
Brazil 112013015204 ⤷  Start Trial
Canada 2821756 ⤷  Start Trial
Canada 3115370 ⤷  Start Trial
Canada 3115378 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.